ASCC3 and rectal cancer: As shown in Figures 3A–D and Supplementary Figure S2, the results indicate that among the 166 rectal cancer patient samples from the TCGA dataset, patients with high ASCC3 expression had significantly better survival rates (Log-rank test: p = 0.012; Cox regression test: HR = 0.36 (0.16–0.83), p = 0.016).